Top Tweets for #Protacs
🧬 Beyond Protein Degradation: 10 #CIP Strategies
Chemically Induced Proximity (#CIP) is expanding targeted protein modulation beyond degradation—reshaping protein interactions, localization, and cellular functions.
🔬 ① Targeted Protein Degradation: #PROTACs, #LYTACs, #AUTACs, #ATTECs, #SNIPERs & Molecular Glue Degraders.
🔬 ② Beyond Degradation: #RIPTACs, #TCIPs, #TRAMs & #DALTACs.
While PROTACs and molecular glue degraders have FDA-approved examples, other approaches are advancing through preclinical and clinical development.
🧪 Explore MCE's E3 ligase ligands, screening libraries, research services & compound customization.
🔗 https://t.co/kIX5hTusq6

Dysregulation of #Ubiquitination pathways contributes to various human diseases.
This review explores its therapeutic potential, including #PROTACs and #MolecularGlues that harness the pathway to target disease-related proteins. @SCUCN
#STTT #OpenAccess: https://t.co/EZTK4jeHLE

How Cancer-Causing Proteins Accumulate May Shape Response to PROTACs
How oncogenes increase protein levels may shape PROTAC response and help identify tumors most likely to benefit from targeted #proteindegradation
@EdinburghUni
#cancers #PROTACs
https://t.co/qRhEArbCLF
🤝MedChemExpress on the Move | See you in Boston!
We’re heading to the 24th Annual Discovery on Target Meeting! @BostonDOT
📅 September 28–October 1, 2026
📍 Boston, MA
📌 Booth #505
Meet us and explore MCE’s solutions for:
💠 AI-Powered #DrugDiscovery
💠 #PROTACs & #MolecularGlues
💠#ADC & Linker-Payload Solutions
💠 #mRNA & #LNP Technologies
Looking forward to connecting with you in Boston! 💜
https://t.co/S2J0ha9Byg
#DiscoveryOnTarget #DOT2026 #MedChemExpress #DrugDiscovery

New in the August 15 issue—Targeted KRASG12V Degradation In Vivo Elicits #LungAdenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis https://t.co/YdOq5S82pS @CrisMayorRuiz #KRAS #PROTACs #ProteinDegradation #LUAD

🔬New Releases | 1,000+ novel research molecules
Expanding #Oncology, #Neurology, #Immunology & Inflammation, and #MetabolicDisease for drug discovery and basic research. Includes #PROTACs, #ADAR1 RNA editing, neuroinflammation targets (TREM2/NLRP3), inflammatory pathways, and bone metabolism (RANKL).
🔬New Releases | 1,000+ Novel Research Molecules Now Available
This release strengthens key areas across #Oncology, #Neurology, #Immunology & #Inflammation, #MetabolicDisease, supporting a broad range of drug discovery and basic research needs.
Featured research areas include:
✔ #PROTAC-mediated targeted protein degradation
✔ RNA editing regulation (#ADAR1)
✔ Neuroinflammation & innate immunity (TREM2, NLRP3)
✔ Inflammatory signaling pathways (PDE4B, IL-36R, LPAR1)
✔ Bone metabolism regulation (RANKL)
Many of these compounds feature desirable drug-like properties, including oral bioavailability, blood–brain barrier (#BBB) penetration, high selectivity, and favorable pharmacokinetic profiles—supporting target validation, mechanistic studies, and early-stage drug discovery.
🔬Empowering breakthrough research with high-quality bioactive molecules. https://t.co/NlSVcuDiTc
#DrugDiscovery #Neuroinflammation #SmallMolecules #ResearchTools

🆕New Releases | 1,000+ Novel Research Molecules Now Available
Discover our latest bioactive molecules designed to advance research in #Oncology, #Neurology, #Immunology & #Inflammation, and #MetabolicDisease.
�� Featured research areas:
✔ PRMT5/MEP50 #PROTACs for targeted protein degradation
✔ EXO1 inhibitors for DNA repair research
✔ Sec61 inhibitors for protein translocation studies
✔ 5-HT7 & FGFR modulators for CNS research
✔ JAK1/2, HDAC5 & TRIM21 modulators for immune signaling
✔ DCSTAMP & CAR/PXR modulators for bone and metabolic disease research
Many of these newly released compounds offer:
✅ High selectivity
✅ Oral bioavailability
✅ BBB penetration
✅ Favorable pharmacokinetic profiles
✅ Clinical-stage validation
Whether you're exploring target discovery, mechanism of action, or translational drug research, these new molecules provide powerful tools to advance your research.
🔗 Explore the latest releases: https://t.co/NlSVcuDiTc
#DrugDiscovery #Oncology #Neuroscience #Immunology #MetabolicDisease #SmallMolecules #ResearchTools #LifeScience

Poor ocular drug delivery limits treatment for choroidal #Neovascularization.
This study in #STTT develops tetrahedral DNA nano-#PROTACs that enhance ocular penetration and degrade #Nucleolin to suppress pathological #Angiogenesis.
#OpenAccess: https://t.co/bKgAMgWmnU

This review discusses #BCL2 family biology and emerging targeted therapies, including BH3 mimetics and #PROTACs, underscoring their therapeutic potential across cancer and other apoptosis-related diseases. @goetheuni
#STTT #OpenAccess: https://t.co/lxSV3RClCt

Congrats to @ines_4412, PhD in our team, on her first first-author paper! 😉 #KRAS #TPD #PROTACs #LUAD #IRBBarcelona
A great collaboration with the Santamaría (@ciccancer) and Riera labs (@URSAchemlab, #IRB), among many other friends and colleagues!
Now online: Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis https://t.co/YdOq5S82pS

We’re going to Nucleate Activator 🚀
Excited to join the 2026 cohort and build with Moktra Bio as Head of Bio.
Working on next-gen #PROTACs for auto-inflammatory diseases
Grateful to the @NucleateHQ ecosystem for backing founders and scientific builders.
Let’s build 🏗️
📢 #SEQT_articles
"First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria "
@MedChemLab_ucm, @quimicasUCM
#PROTACs #Progeria #Senescence #Progerin

🥳 Our 2nd most downloaded article in 2025:
Targeted protein degradation for cancer therapy
#PROTACs #Degraders @NatResCancer
#NRCtop10of2025
https://t.co/fJYvY5rAhq
PROTACs (PROteolysis TArgeting Chimeras) are revolutionizing drug discovery by degrading disease-causing proteins. These small molecules bring together target proteins with cellular disposal systems for precise therapeutic action. #PROTACs #PrecisionMedicine
5 years ago the optimization of #PROTACs for oral bioavailability was seen as a daunting task. The task has been solved by relying heavily on in vivo PK studies. Now the understanding is growing how in vitro assays can guide optimization: //www.mdpi.com/1424-8247/18/4/568k

🌿TAPTAC1 is a new PROTAC with three distinct mechanisms that reactivate apoptosis in wild-type (normal) p53 cancers.
#PROTACs #p53 #肉腫 #sarcoma #cancer
🔶Until now, cancers with normal p53 have been difficult to treat.
→ This is because p53 protects cancer cells.
🔶The new PROTAC drug developed by our research team, TAPTAC1, does three things simultaneously:
1. Degrades p53
2. Blocks p53 function
3. Destroys the cancer factory (nucleolus)
🔶Results:
Wild-type (normal) p53 cancers were killed, and tumors shrank dramatically. TAPTAC1 has been shown to be particularly sensitive to melanoma, skin cancer, kidney cancer, soft tissue sarcoma, hematopoietic cancer, and ovarian cancer.
Furthermore, normal cells were barely harmed.
🎠PROTAC TAPTAC1 is a promising new treatment.

🔥🔥Excited to present our latest work on expanding the toolbox of ligandable E3 ligases. #TPD #E3ligases #PROTACS. A work led by researchers at @UniBarcelona, @IBUB_UB, @IQTCUB, in collaboration with @keserulab and Bing Hao lab (@UConn ).
https://t.co/361pMfgI6p
We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world.
Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible.
Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: https://t.co/rZ4WnE54IS
#RevolutionizingImmunology
Last Seen Hashtags on Sotwe
travelnudespain
Seen from Netherlands
BustyBeauty
แตกใส่นม
Seen from Thailand
女装男子
Seen from Germany
gaywetsuit
allowflash()******************************************************
Seen from Turkey
تركيات
sexyhunk
Seen from Indonesia
bnwo genetics
Seen from Italy
anxiouspanda()****************************************************************** filter:videos
Seen from United Kingdom
Trends for you
Most Popular Users

Elon Musk 
@elonmusk
240.7M followers

Barack Obama 
@barackobama
118.7M followers

Cristiano Ronaldo 
@cristiano
114.5M followers

Donald J. Trump 
@realdonaldtrump
111.9M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.4M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.7M followers

Neymar Jr 
@neymarjr
66.4M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63.1M followers

The Ellen Show
@theellenshow
62.1M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers














